RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+43%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$926M
AUM Growth
+$926M
(+30%)
Cap. Flow
-$7.41M
Cap. Flow
% of AUM
-0.8%
Top 10 Holdings %
Top 10 Hldgs %
29.66%
Holding
99
New
14
Increased
25
Reduced
45
Closed
5
Top Buys
| 1 |
Gilead Sciences
GILD
|
$17.7M |
| 2 |
LVGO
Livongo Health, Inc. Common Stock
LVGO
|
$9.4M |
| 3 |
Baxter International
BAX
|
$8.18M |
| 4 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$8.1M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
$7.8M |
Top Sells
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$13.9M |
| 2 |
MacroGenics
MGNX
|
$9.07M |
| 3 |
Esperion Therapeutics
ESPR
|
$8.61M |
| 4 |
Neurocrine Biosciences
NBIX
|
$6.71M |
| 5 |
Nektar Therapeutics
NKTR
|
$6.6M |
Sector Composition
| 1 | Healthcare | 94.86% |
| 2 | Communication Services | 1.03% |
| 3 | Energy | 0.07% |
| 4 | Technology | 0.06% |
| 5 | Financials | 0.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SWAV
76
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
| $2.84M | 0.31% |
+60,000
| New | +$2.84M |
|
77
Abeona Therapeutics
ABEO
$356M
| $2.7M | 0.29% |
925,000
-25,000
| -3% | -$72.9K |
|
|
CLLS
78
Cellectis
CLLS
$260M
| $2.57M | 0.28% |
144,604
| – | – |
|
79
uniQure
QURE
$954M
| $1.82M | 0.2% |
40,466
-25,332
| -38% | -$1.14M |
|
|
VRAY
80
DELISTED
ViewRay, Inc.
VRAY
| $1.74M | 0.19% |
775,000
-75,000
| -9% | -$168K |
|
|
PVLA
81
Palvella Therapeutics, Inc. Common Stock
PVLA
$592M
| $930K | 0.1% |
300,000
| – | – |
|
82
Chevron
CVX
$318B
| $265K | 0.03% |
2,974
| – | – |
|
83
Exxon Mobil
XOM
$477B
| $241K | 0.03% |
5,388
| – | – |
|
84
Qualcomm
QCOM
$170B
| $217K | 0.02% |
+2,381
| New | +$217K |
|
85
IBM
IBM
$227B
| $192K | 0.02% |
1,587
-628
| -28% | -$76K |
|
86
Janus Henderson
JHG
$6.86B
| $183K | 0.02% |
8,645
-2,000
| -19% | -$42.3K |
|
87
Ford
F
$46.2B
| $177K | 0.02% |
29,164
| – | – |
|
88
JPMorgan Chase
JPM
$824B
| $162K | 0.02% |
+1,723
| New | +$162K |
|
89
Walt Disney
DIS
$211B
| $149K | 0.02% |
+1,338
| New | +$149K |
|
90
Pfizer
PFE
$141B
| $147K | 0.02% |
+4,508
| New | +$147K |
|
91
AB InBev
BUD
$116B
| $138K | 0.01% |
+2,806
| New | +$138K |
|
92
Gen Digital
GEN
$18.3B
| $137K | 0.01% |
+6,926
| New | +$137K |
|
93
Wells Fargo
WFC
$258B
| $135K | 0.01% |
+5,272
| New | +$135K |
|
94
Halliburton
HAL
$18.4B
| $108K | 0.01% |
+8,299
| New | +$108K |
|
|
STML
95
DELISTED
Stemline Therapeutics, Inc.
STML
| – | – |
-650,000
| Closed | -$3.15M |
|
|
ICPT
96
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| – | – |
-40,000
| Closed | -$2.52M |
|
|
ONC
97
BeOne Medicines Ltd. American Depositary Shares
ONC
$37B
| – | – |
-20,000
| Closed | -$2.46M |
|
98
Viking Therapeutics
VKTX
$3.02B
| – | – |
-200,000
| Closed | -$936K |
|
|
SAGE
99
DELISTED
Sage Therapeutics
SAGE
| – | – |
-50,000
| Closed | -$1.44M |
|